Evogene (EVGN) Misses Q4 EPS by 5c

Evogene (NYSE: EVGN) reported Q4 EPS of ($0.22), $0.05 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $2.46 million versus the consensus estimate of $3.9 million.

For earnings history and earnings-related data on Evogene (EVGN) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Redburn upgrades Southwest, stays bullish on Delta and United
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2